Compare D R Horton Inc (DHI) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Gilead Sciences, Inc. — how do they compare? D R Horton Inc trades at $135.82 (market cap $37.99B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 4.8× D R Horton Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Gilead Sciences, Inc. for 111 Days on average.
| DHI | GILD | |
|---|---|---|
Market Cap | $37.99B | $182.40B |
Volume | 2,974,460 | 4,469,821 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $155.80 |
52-Week Low | $132.53 | $116.74 |
Typical Hold Time | 46 Days | 111 Days |
Enterprise Value | $43.09B | $205.46B |
Dividend Yield | 1.33% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) is trading at $133.28, down 2.54% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 12.71 and P/S of 1.16, while maintaining solid profitability with 9.15% net margin. Recent earnings have consistently beaten expectations, though revenue declined to $34.25B in 2025. Technical indicators show oversold conditions with RSI at 26.75, while analyst consensus remains positive with $156.57 price target.
DHI presents a value opportunity with strong fundamentals but faces near-term headwinds from rising mortgage rates and housing market weakness. The 47% upside to consensus target offers potential reward, though investors must weigh housing sector volatility against the company's consistent execution and shareholder returns including dividends and buybacks.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
